JP4471498B2 - ジホスホン酸を含有する組成物 - Google Patents

ジホスホン酸を含有する組成物 Download PDF

Info

Publication number
JP4471498B2
JP4471498B2 JP2000575516A JP2000575516A JP4471498B2 JP 4471498 B2 JP4471498 B2 JP 4471498B2 JP 2000575516 A JP2000575516 A JP 2000575516A JP 2000575516 A JP2000575516 A JP 2000575516A JP 4471498 B2 JP4471498 B2 JP 4471498B2
Authority
JP
Japan
Prior art keywords
dosage form
granules
stearic acid
weight
active substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2000575516A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002527398A (ja
Inventor
ガーベル，ロルフ−ディーター
プライス，ヴァルター
ヴォーク，ハインリヒ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8232769&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4471498(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2002527398A publication Critical patent/JP2002527398A/ja
Application granted granted Critical
Publication of JP4471498B2 publication Critical patent/JP4471498B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2000575516A 1998-10-09 1999-10-01 ジホスホン酸を含有する組成物 Expired - Lifetime JP4471498B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98119102.6 1998-10-09
EP98119102A EP0998932A1 (de) 1998-10-09 1998-10-09 Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
PCT/EP1999/007287 WO2000021540A1 (en) 1998-10-09 1999-10-01 Compositions containing diphosphonic acids

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010009189A Division JP2010116408A (ja) 1998-10-09 2010-01-19 ジホスホン酸を含有する組成物

Publications (2)

Publication Number Publication Date
JP2002527398A JP2002527398A (ja) 2002-08-27
JP4471498B2 true JP4471498B2 (ja) 2010-06-02

Family

ID=8232769

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000575516A Expired - Lifetime JP4471498B2 (ja) 1998-10-09 1999-10-01 ジホスホン酸を含有する組成物
JP2010009189A Pending JP2010116408A (ja) 1998-10-09 2010-01-19 ジホスホン酸を含有する組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010009189A Pending JP2010116408A (ja) 1998-10-09 2010-01-19 ジホスホン酸を含有する組成物

Country Status (35)

Country Link
US (2) US6294196B1 (he)
EP (2) EP0998932A1 (he)
JP (2) JP4471498B2 (he)
KR (1) KR100522505B1 (he)
CN (1) CN1150000C (he)
AR (3) AR014081A1 (he)
AT (1) ATE311887T1 (he)
AU (1) AU752532B2 (he)
BR (1) BR9914367A (he)
CA (1) CA2346662C (he)
CO (1) CO5050325A1 (he)
CY (1) CY1105437T1 (he)
CZ (1) CZ299008B6 (he)
DE (1) DE69928819T2 (he)
DK (1) DK1117412T3 (he)
ES (1) ES2253919T3 (he)
HK (1) HK1040914B (he)
HR (1) HRP20010243B1 (he)
HU (1) HU226457B1 (he)
ID (1) ID29876A (he)
IL (3) IL141912A0 (he)
MA (1) MA27123A1 (he)
ME (1) ME00637B (he)
MY (1) MY126625A (he)
NO (1) NO327447B1 (he)
NZ (1) NZ510433A (he)
PE (1) PE20001082A1 (he)
PL (1) PL194552B1 (he)
RS (1) RS49809B (he)
RU (1) RU2207860C2 (he)
SI (1) SI1117412T1 (he)
TR (1) TR200100889T2 (he)
TW (1) TW576742B (he)
WO (1) WO2000021540A1 (he)
ZA (1) ZA200102276B (he)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010116408A (ja) * 1998-10-09 2010-05-27 F Hoffmann La Roche Ag ジホスホン酸を含有する組成物

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL125336A0 (en) 1998-07-14 1999-03-12 Yissum Res Dev Co Compositions for inhibition and treatment of restinosis
US6984400B2 (en) 1998-07-14 2006-01-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of treating restenosis using bisphosphonate nanoparticles
US7008645B2 (en) 1998-07-14 2006-03-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of inhibiting restenosis using bisphosphonates
PL371264A1 (en) * 2001-12-21 2005-06-13 The Procter & Gamble Company Method for the treatment of bone disorders
CA2470495A1 (en) * 2001-12-24 2003-07-17 Teva Pharmaceutical Industries Ltd. Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
ES2532393T3 (es) * 2002-05-10 2015-03-26 F. Hoffmann-La Roche Ag Acidos bisfosfónicos para tratamiento y prevención de osteoporosis
AU2006222690B2 (en) * 2002-12-20 2009-04-23 F. Hoffmann-La Roche Ag High dose ibandronate formulation
DE60315514T3 (de) † 2002-12-20 2012-04-26 F. Hoffmann-La Roche Ag Hochdosierte ibandronat-formulierung
US10517883B2 (en) 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
CA2554749A1 (en) * 2004-01-30 2005-08-11 Astellas Pharma Inc. P2x receptor inhibitor
ES2358269T3 (es) * 2004-08-23 2011-05-09 Teva Pharmaceutical Industries Ltd Forma cristalina del ibandronato sódico y procedimientos para su preparación.
US7358361B2 (en) * 2004-10-08 2008-04-15 The Board Of Trustees Of The University Of Illinois Biophosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
WO2008128056A1 (en) * 2004-10-08 2008-10-23 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including fpps, ggpps, and dpps
EP2662380B1 (en) * 2005-02-01 2018-11-21 Atnahs Pharma UK Limited Medical use of Ibandronate polymorph A
EP1848727B1 (en) * 2005-02-01 2015-06-17 F.Hoffmann-La Roche Ag Ibandronate polymorph b
US20070049557A1 (en) * 2005-08-24 2007-03-01 Hashim Ahmed Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
US20070191315A1 (en) * 2006-02-16 2007-08-16 Bengt Bergstrom Method for administering ibandronate
JP2009530414A (ja) * 2006-03-17 2009-08-27 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ ビスホスホネート化合物及び方法
GB0616794D0 (en) 2006-08-24 2006-10-04 Arrow Int Ltd Solid dosage form
US20080139514A1 (en) * 2006-11-29 2008-06-12 Subhash Pandurang Gore Diphosphonic acid pharmaceutical compositions
CA2570949A1 (en) * 2006-12-12 2008-06-12 Apotex Pharmachem Inc. Ibandronate sodium propylene glycol solvate and processes for the preparation thereof
EP2114455A4 (en) * 2006-12-20 2010-03-17 Mylan Pharmaceuticals Ulc PHARMACEUTICAL COMPOSITION USING A HOT-MELT GRANULATED AGENT
EP2298286B8 (en) * 2009-09-18 2017-08-09 SiTec PharmaBio SL Process for dewatering of product powders
KR101244414B1 (ko) * 2010-11-05 2013-03-18 주식회사 바이오파마티스 고함량 이반드론산 함유 골다공증 예방 또는 치료용 조성물 및 이의 제조방법
WO2012093974A1 (en) 2011-01-06 2012-07-12 Mahmut Bilgic Improved bisphosphonate formulations
JP5874545B2 (ja) * 2011-06-20 2016-03-02 アステラス製薬株式会社 経口投与用医薬組成物
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4639338A (en) 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
DE3434667A1 (de) 1984-09-21 1986-04-03 Henkel KGaA, 4000 Düsseldorf 4-dimethylamino-1-hydroxybutan-1,1-diphosphonsaeure, deren wasserloesliche salze, verfahren zu ihrer herstellung sowie ihre verwendung
US4798725A (en) 1986-06-16 1989-01-17 Norwich Eaton Pharmaceuticals, Inc. Sustained release capsule
DE3623397A1 (de) 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
IL84497A (he) 1986-11-21 1994-10-21 Ciba Geigy Ag תולדות 2-)אימידזול-1-איל( אתאן-1,1- חומצה דיפוספונית, הכנתן ותכשירי רוקחות המכילים אותן
ATE60711T1 (de) * 1986-12-20 1991-02-15 Boehringer Mannheim Gmbh Clodronat-haltige arzneimittel und verfahren zur herstellung derselben.
FR2629716B1 (fr) 1988-04-07 1991-07-19 Sanofi Sa Composition pharmaceutique pour administration orale a base d'un derive d'acide diphosphonique
CZ282760B6 (cs) 1991-11-22 1997-09-17 Procter And Gamble Pharmaceuticals, Inc. Risedronátové prostředky se zpožděným uvolňováním
AU1193092A (en) 1992-01-10 1993-08-03 Obschestvo S Ogranichennoi Otvetstvennostju Meditsinsky Nauchno-Proizvodstvenny Komplex Biotiki Granulated pharmaceutical composition and method of obtaining it
SE501389C2 (sv) * 1992-04-24 1995-01-30 Leiras Oy Farmaceutiskt preparat och förfarande för dess framställning
DE4228552A1 (de) 1992-08-27 1994-03-03 Boehringer Mannheim Gmbh Diphosphonsäuren und deren Salze enthaltende Arzneimittel
US5358941A (en) 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
AU687744B2 (en) 1993-05-15 1998-03-05 Riemser Arzneimittel Ag More easily biologically absorbed tablet containing dichloromethylene diphosphonic acid as the active agent
TW390813B (en) 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
US5656288A (en) * 1995-06-08 1997-08-12 Sanofi Winthrop, Inc. Stable pharmaceutical compositions containing tiludronate hydrates and process for producing the pharmaceutical compositions
IL120265A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis - polyphosphonates or progestins and estrogen agonists
DE19615812A1 (de) 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
EP0998933A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation
EP0998932A1 (de) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010116408A (ja) * 1998-10-09 2010-05-27 F Hoffmann La Roche Ag ジホスホン酸を含有する組成物

Also Published As

Publication number Publication date
CO5050325A1 (es) 2001-06-27
KR20010073203A (ko) 2001-07-31
AR014081A1 (es) 2001-01-31
DE69928819T2 (de) 2006-07-20
CZ20011233A3 (cs) 2001-09-12
HU226457B1 (en) 2008-12-29
EP1117412A1 (en) 2001-07-25
ME00637B (me) 2008-08-07
RS49809B (sr) 2008-08-07
IL177940A0 (en) 2006-12-31
DK1117412T3 (da) 2006-04-03
JP2002527398A (ja) 2002-08-27
EP1117412B1 (en) 2005-12-07
JP2010116408A (ja) 2010-05-27
CY1105437T1 (el) 2010-04-28
HRP20010243B1 (en) 2011-02-28
NO20011714D0 (no) 2001-04-05
HUP0103931A2 (en) 2002-06-29
NZ510433A (en) 2003-08-29
IL177940A (he) 2012-05-31
CA2346662C (en) 2006-05-09
US20020006441A1 (en) 2002-01-17
ES2253919T3 (es) 2006-06-01
NO327447B1 (no) 2009-06-29
SI1117412T1 (sl) 2006-04-30
MY126625A (en) 2006-10-31
HK1040914A1 (en) 2002-06-28
CZ299008B6 (cs) 2008-04-02
DE69928819D1 (de) 2006-01-12
NO20011714L (no) 2001-04-05
YU20501A (sh) 2003-02-28
WO2000021540A1 (en) 2000-04-20
CN1319015A (zh) 2001-10-24
EP0998932A1 (de) 2000-05-10
PE20001082A1 (es) 2000-10-18
KR100522505B1 (ko) 2005-10-18
AU752532B2 (en) 2002-09-19
ID29876A (id) 2001-10-18
AR069942A2 (es) 2010-03-03
ATE311887T1 (de) 2005-12-15
US6294196B1 (en) 2001-09-25
HRP20010243A2 (en) 2002-04-30
PL347243A1 (en) 2002-03-25
TW576742B (en) 2004-02-21
TR200100889T2 (tr) 2001-07-23
IL141912A (he) 2006-12-10
BR9914367A (pt) 2001-06-26
CA2346662A1 (en) 2000-04-20
US6627221B2 (en) 2003-09-30
HUP0103931A3 (en) 2003-01-28
IL141912A0 (en) 2002-03-10
ZA200102276B (en) 2002-06-19
MA27123A1 (fr) 2005-01-03
CN1150000C (zh) 2004-05-19
PL194552B1 (pl) 2007-06-29
HK1040914B (zh) 2004-12-10
AU6467599A (en) 2000-05-01
AR047815A2 (es) 2006-02-22
RU2207860C2 (ru) 2003-07-10

Similar Documents

Publication Publication Date Title
JP4471498B2 (ja) ジホスホン酸を含有する組成物
JP3725427B2 (ja) ビホスホネートを含む経口医薬品組成物の製造方法
KR100694550B1 (ko) 고용량의 이반드로네이트 제형물
MXPA01003435A (en) Compositions containing diphosphonic acids
AU2006222690B2 (en) High dose ibandronate formulation
MX2007014056A (es) Composicion farmaceutica solida para administracion oral de acido ibandronico o una sal o un hidrato farmaceuticamente aceptable del mismo, procedimiento de preparacion de dicha composicion mediante compresion directa, formulaciones farmaceuticas que

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20040413

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20040624

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20040714

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041012

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20050405

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20050704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20050704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100119

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100302

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130312

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4471498

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130312

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140312

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term